MAPT and Alzheimer disease: In the present study, based on our previous research work [31], we aimed to detect serum SIRT1, Aβ1-42, T-tau, and P-tau-181 protein levels in AD, MCI patients, and normal controls (NCs), and assess their potential as early diagnostic biomarkers for AD.